At the conclusion of this application-based activity, participants will be able to:
  • Review the molecular pathology of advanced non-small cell lung cancer (NSCLC) and identify clinically relevant molecular mutations that impact treatment selection.
  • Examine strategies to coordinate care in the community setting to improve adherence to guideline-recommended molecular testing in NSCLC and discuss the utility of newer technologies such as ctDNA liquid biopsy in clinical practice.
  • Evaluate targeted treatment options for actionable and acquired mutations in NSCLC, such as EGFR/T790M, and assess the safety and efficacy of these targeted therapies.
  • Using a case-based approach, examine how to best incorporate molecular testing to optimize targeted therapy selection in EGFR-mutated NSCLC at initiation of therapy and upon disease progression.